ADMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ADMA Biologics Inc is not an ideal buy for a beginner investor with a long-term focus at this moment. The technical indicators show bearish trends, options data reflects a strong bearish sentiment, and while the company has shown revenue growth, its net income and EPS have significantly declined. The lack of recent congress trading data and no strong proprietary trading signals further support a hold recommendation.
The stock is showing bearish momentum with a negatively expanding MACD histogram (-0.0269), RSI at 29.039 (neutral but close to oversold), and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support is at $15, with resistance at $16.57. The stock has a 40% chance of declining by -2.71% in the next day and a 17.47% chance of increasing in the next month.
Hedge funds are significantly increasing their positions in ADMA, with a 719.51% increase in buying over the last quarter. Revenue for Q4 2025 grew by 18.39% YoY, and gross margin increased by 84.42% YoY.
The MACD and moving averages indicate bearish momentum. The lack of recent insider activity and no congress trading data further dampens confidence.
In Q4 2025, ADMA reported revenue growth of 18.39% YoY to $139.16 million. However, net income fell sharply by -55.87% YoY to $49.38 million, and EPS dropped by -55.56% YoY to $0.20. Gross margin improved significantly, rising by 84.42% YoY to 99.33%.
No recent analyst rating or price target changes were provided. However, the stock's bearish technical indicators and weak financial performance suggest limited upside potential in the near term.
